Showing 1651-1660 of 10035 results for "".
Aubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tAAD Highlights; Cyndi Lauper on Psoriasis; Qilib and More
https://practicaldermatology.com/topics/psoriasis/dermwiretv-aad-highlights-cyndi-lauper-on-psoriasis-qilib-and-more/18806/Highlights from the educational sessions at the AAD Annual Meeting; Cyndi Lauper Says there's more to Psoriasis. Galderma Launches qilib and more from the exhibit hall at AAD. Plus SkinCeuticals opens Male Aesthetics Center in DC.Allergan Board Rejects Latest Valeant Bid; Topical Jublia Approved for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dwtv-6-12/19122/Allergan's board rejects the latest merger proposal from Valeant and the FDA approves topical Jublia for onychomycosis. LEarn about these developments and hear from the AMA's new president in this edition of DermWireTV.Vitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.DermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisStraight Scoop: Audience Questions Answered
https://practicaldermatology.com/topics/practice-management/straight-scoop-audience-questions-answered/19820/The panelists respond to questions from the audience about negotiating, choosing opportunities, and even how to say "No" the right way.DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cosmetic-surgery-forum-highlights-leo-focuses-on-ad/19703/New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic derDermWireTV: Cassiopea NDA; Drew Barrymore and Paula Abdul Make Endorsements
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cassiopea-nda-drew-barrymore-and-paula-abdul-make-endorsements/19654/BTL’s new Emtone device targets cellulite via simultaneous thermal monopolar radiofrequency and mechanical targeted pressure energy to increase production of collagen and elastin. Drew Barrymore is brand ambassador for Emsculpt. Cassiopea has submitted a New Drug Application to the FDA seeking markeGalderma, Allergan Rosacea News, Dupilumab Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-allergan-rosacea-news-dupilumab-data/18591/Galderma Laboratories launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33. The FDA has accepted Allergan's New Drug Application (NDA) filing for oxymetazoline cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema asso